OMEGA DIAGNOSTICS GROUP PLC
("Omega" or the "Company" or the "Group")
Launch of COVID-19 antibody laboratory-based testing service
Omega (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance, announces that it has launched the Mologic ELISA1 antibody test for COVID-19 through its in-house testing laboratory service in Littleport, Cambridgeshire.
This follows the successful CE marking of the capillary blood sample collection pack which is sent to healthcare professionals who then send the patient's sample back to the Company's laboratory, where the test is then run. Test results are then sent back to each healthcare professional who informs the patient of their result and provides advice as necessary.
The Company expects to offer this testing service to selected commercial occupational health partners, clinics and health care professionals in the UK.
Colin King, CEO of Omega commented: "We are pleased that we have delivered on our committed timeline for the launch of the lab testing service. This highlights our ability to react to changing market needs and utilises the skills and expertise of our long-established service Laboratory."
1 ELISA (Enzyme Linked Immuno-Sorbent Assay) tests are one of the most tested and proven laboratory technologies used by the global diagnostic industry and remain the principal reference point from which rapid diagnostics are coordinated, especially serological tests, including tests for COVID-19.
Contacts:
| Omega Diagnostics Group PLC | Tel: 01259 763 030 |
| Bill Rhodes, Interim Non-Executive Chairman Colin King, Chief Executive | |
| Kieron Harbinson, Group Finance Director | |
| | |
| finnCap Ltd | Tel: 020 7220 0500 |
| Geoff Nash/Edward Whiley (Corporate Finance) | |
| Alice Lane (ECM) | |
| | |
| Walbrook PR Limited | Tel: 020 7933 8780 or omega@walbrookpr.com |
| Paul McManus | Mob: 07980 541 893 |
| Lianne Cawthorne | Mob: 07584 391 303 |
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
